Cargando…

Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis

BACKGROUND: The utility of novel oral soluble guanylate cyclase (sGC) stimulators (vericiguat and riociguat), in patients with reduced or preserved ejection fraction heart failure (HFrEF/HFpEF) is currently unclear. AIM: To determine the efficacy and safety of sGC stimulators in HF patients. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ullah, Waqas, Mukhtar, Maryam, Al-Mukhtar, Aws, Saeed, Rehan, Boigon, Margot, Haas, Donald, Rame, Eduardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596421/ https://www.ncbi.nlm.nih.gov/pubmed/33173569 http://dx.doi.org/10.4330/wjc.v12.i10.501

Ejemplares similares

Effects of left ventricular assist device on pulmonary functions and pulmonary hemodynamics: A meta-analysis. waqasullah.dr@gmail.com
por: Ullah, Waqas, et al.
Publicado: (2020)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

The discovery and characterization of novel soluble guanylate cyclase stimulators
por: Masferrer, Jaime L
Publicado: (2015)

Comparative safety of percutaneous ventricular assist device and intra-aortic balloon pump in acute myocardial infarction-induced cardiogenic shock
por: Ullah, Waqas, et al.
Publicado: (2021)

Probing the Structural Dynamics of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Khalid, Rana Rehan, et al.
Publicado: (2020)

Activation mechanism of human soluble guanylate cyclase by stimulators and activators
por: Liu, Rui, et al.
Publicado: (2021)

Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)

Stimulators and Activators of Soluble Guanylate Cyclase: Review and Potential Therapeutic Indications
por: Nossaman, Bobby, et al.
Publicado: (2012)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
por: Frey, Reiner, et al.
Publicado: (2013)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
por: Lian, Tian-Yu, et al.
Publicado: (2017)

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
por: Huang, Dong-Hui, et al.
Publicado: (2016)

Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
por: Evgenov, Oleg V, et al.
Publicado: (2011)

Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease
por: Ghanta, Mohankrishna, et al.
Publicado: (2017)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
por: Wittenborn, Elizabeth C., et al.
Publicado: (2021)

The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis
por: Zheng, Xiaoyu, et al.
Publicado: (2018)

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
por: Schwabl, Philipp, et al.
Publicado: (2018)

Stimulation of soluble guanylate cyclase improves donor organ function in rat heart transplantation
por: Benke, Kálmán, et al.
Publicado: (2020)

Vasoprotection by heme oxygenase-1: interactions with soluble guanylate cyclase
por: Durante, William
Publicado: (2011)

Crystal Structures of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Allerston, Charles K., et al.
Publicado: (2013)

A new small molecule inhibitor of soluble guanylate cyclase
por: Mota, Filipa, et al.
Publicado: (2015)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
por: Witte, Jeannine, et al.
Publicado: (2018)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Stimulation of soluble guanylate cyclase accelerates renal recovery following relief of unilateral ureteral obstruction
por: Wang-Rosenke, Yingrui, et al.
Publicado: (2009)

Comparison of Soluble Guanylate Cyclase Stimulators and Activators in Models of Cardiovascular Disease Associated with Oxidative Stress
por: Costell, Melissa H., et al.
Publicado: (2012)

The Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes
por: Ge, Pei, et al.
Publicado: (2016)

Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease
por: Paul, Tanja, et al.
Publicado: (2018)

First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension
por: Spreemann, Till, et al.
Publicado: (2017)

Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy
por: Hu, Lufei, et al.
Publicado: (2022)

Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy
por: Hu, Bo-ang, et al.
Publicado: (2023)

As the COVID-19 pandemic drags on, where have all the STEMIs gone?
por: Ullah, Waqas, et al.
Publicado: (2020)

Thrombospondin-1 is a universal inhibitor of soluble guanylate cyclase activation
por: Miller, Thomas W, et al.
Publicado: (2009)

Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow
por: Rogers, Natasha M., et al.
Publicado: (2014)

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma
por: Buys, Emmanuel S., et al.
Publicado: (2014)

Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development
por: Gileadi, Opher
Publicado: (2014)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

The soluble guanylate cyclase stimulator IW‐1973 prevents inflammation and fibrosis in experimental non‐alcoholic steatohepatitis
por: Flores‐Costa, Roger, et al.
Publicado: (2018)

Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension
por: Murata, Mitsushige, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jvh9k8pjlu66c823bntq3j3mvp